MX2021012728A - Combinación de dosis fija de antihipertensivo y reductor de colesterol y método de fabricación. - Google Patents

Combinación de dosis fija de antihipertensivo y reductor de colesterol y método de fabricación.

Info

Publication number
MX2021012728A
MX2021012728A MX2021012728A MX2021012728A MX2021012728A MX 2021012728 A MX2021012728 A MX 2021012728A MX 2021012728 A MX2021012728 A MX 2021012728A MX 2021012728 A MX2021012728 A MX 2021012728A MX 2021012728 A MX2021012728 A MX 2021012728A
Authority
MX
Mexico
Prior art keywords
dose combination
cholesterol
fixed
hypertensive
lowering
Prior art date
Application number
MX2021012728A
Other languages
English (en)
Inventor
Roy A Stimits
Jr Dr Daniel Tyree Gregory
Wayne L Whittingham
Dr Stephan Dale Glenn
David P Hause
Original Assignee
Cardiopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiopharma Inc filed Critical Cardiopharma Inc
Publication of MX2021012728A publication Critical patent/MX2021012728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se divulga un método de fabricación de una forma farmacéutica combinada de dosis fija cardiovascular que incluye un agente activo antihipertensivo, un agente activo reductor del colesterol y, opcionalmente, una aspirina o un inhibidor de plaquetas con revestimiento entérico. La combinación de dosis fija se prepara con al menos dos soluciones de granulación que están desprovistas de ácido cítrico y mejoran la solubilidad acuosa del agente reductor del colesterol en la combinación de dosis fija. Los agentes activos en la forma farmacéutica resultante, que está desprovista de ácido cítrico, tienen la misma concentración y los mismos perfiles de liberación que los mismos agentes activos preparados en una formulación simple.
MX2021012728A 2019-04-17 2019-04-17 Combinación de dosis fija de antihipertensivo y reductor de colesterol y método de fabricación. MX2021012728A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/027936 WO2020214163A1 (en) 2019-04-17 2019-04-17 Anti-hypertensive and cholesterol-lowering fixed-dose combination and method of manufacture

Publications (1)

Publication Number Publication Date
MX2021012728A true MX2021012728A (es) 2022-01-24

Family

ID=72833469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012728A MX2021012728A (es) 2019-04-17 2019-04-17 Combinación de dosis fija de antihipertensivo y reductor de colesterol y método de fabricación.

Country Status (10)

Country Link
US (1) US11737988B2 (es)
EP (1) EP3955912A4 (es)
AU (1) AU2019441241B2 (es)
CA (2) CA3235781A1 (es)
EA (1) EA202192854A1 (es)
IL (1) IL287299B1 (es)
JO (1) JOP20210280A1 (es)
MX (1) MX2021012728A (es)
WO (1) WO2020214163A1 (es)
ZA (1) ZA202107873B (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
CA2483099A1 (en) * 2002-05-03 2003-11-13 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
BRPI0412557A (pt) * 2003-07-28 2006-09-19 Reddys Lab Inc Dr forma de dosagem farmacêutica de eventos cardiovasculares
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2006085128A1 (en) * 2005-02-09 2006-08-17 Wockhardt Limited Cardiovascular therapeutic combinations
US20100310607A1 (en) 2005-04-08 2010-12-09 Abbott Laboratories Pharmaceutical formulations
CN101590232A (zh) 2008-05-29 2009-12-02 北京奥萨医药研究中心有限公司 血管紧张素转化酶抑制剂、他汀类降脂药和烟酸的药物组合物及其用途
CN101632673B (zh) 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
CA2754134C (en) * 2009-02-11 2018-09-18 Cadila Pharmaceuticals Ltd. Stable pharmaceutical composition for atherosclerosis
EP2405747A4 (en) 2009-03-13 2013-01-16 Nucitec Sa De Cv COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
EP2424509A4 (en) 2009-04-30 2012-11-07 Reddys Lab Ltd Dr MEDICINAL COMBINATION FORMULATIONS WITH DETERMINED DOSAGE
KR101771766B1 (ko) 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
US11622939B2 (en) * 2017-11-23 2023-04-11 Zhejiang Hisun Pharmaceutical Co., Ltd. HS-25 tablet and preparation method therefor

Also Published As

Publication number Publication date
CA3136797C (en) 2024-05-28
JOP20210280A1 (ar) 2023-01-30
ZA202107873B (en) 2022-06-29
IL287299A (en) 2022-07-01
AU2019441241A1 (en) 2021-11-18
WO2020214163A1 (en) 2020-10-22
US20200330391A1 (en) 2020-10-22
IL287299B1 (en) 2024-06-01
AU2019441241B2 (en) 2023-11-23
US11737988B2 (en) 2023-08-29
EA202192854A1 (ru) 2022-01-28
CA3235781A1 (en) 2020-10-22
CA3136797A1 (en) 2020-10-22
EP3955912A4 (en) 2022-12-14
EP3955912A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
CO6290635A2 (es) Composición farmaceútica que comprende una forma de dosis unitaria sólida de uno o más ingredientes activos y un polímero insoluble en agua y/o un polímero soluble en agua
PH12015501015B1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2017037594A3 (zh) 用于减少局部脂肪的医药组成物及其用途
NZ631100A (en) Soft chewable pharmaceutical products
WO2014170755A3 (en) Sustained-release formulations of colchicine and methods of using same
AR105203A1 (es) Formulación oral sólida que contiene irinotecán y método de preparación de la misma
WO2015038552A3 (en) Aspirin formulation for increased efficacy
WO2014016671A3 (en) Formulations and methods of manufacturing formulations for use in colonic evacuation
MX2022007707A (es) Comprimidos de edoxaban.
PH12019500919A1 (en) Esomeprazole~containing complex capsule and preparation method therefor
MX2021012728A (es) Combinación de dosis fija de antihipertensivo y reductor de colesterol y método de fabricación.
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
MX2021001145A (es) Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico.
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
MX2021011795A (es) Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble.
MX2021008248A (es) Composicion farmaceutica.
MX336065B (es) Composiciones con liberacion rapida de farmaco.
MX2021002459A (es) Formas de dosificacion en capsula disuasorias del abuso de liberacion inmediata.
MX2021013488A (es) Formulaciones liquidas de dosis oral de metilnaltrexona.
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
EP3604317A4 (en) POLYFLUOROALKYL PHOSPHORIC ACID ESTERS OR SALT THEREOF AND RELEASE AGENTS THEREFORE AS THE ACTIVE SUBSTANCE
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.
AR100920A1 (es) Composiciones antimicrobianas con agentes efervescentes, método
PL419082A1 (pl) Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol